This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Leishmania Infantum Disease
Information about Leishmania Infantum Disease: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Leishmania Infantum Disease
Most recent studies have shown that Leishmania Infantum Disease shares some biological mechanisms with aids-related-opportunistic-infections, asymptomatic-infections, cat-diseases, chagas-disease, coinfection, communicable-diseases, delayed-hypersensitivity, dog-diseases, endemic-diseases, hiv-infections, immunologic-deficiency-syndromes, infective-disorder, leishmaniasis, leishmaniasis-cutaneous, leishmaniasis-visceral, mucocutaneous-leishmaniasis, opportunistic-infections, parasitemia, zoonoses.
Among the many pathways, these few ones have gauged particular interests from scientists studying Leishmania Infantum Disease, and have been seen in publications frequently: Cell Activation, Cell Death, Cell Division, Cell Proliferation, Cytokine Production, Drug Resistance, Humoral Immune Response, Hypersensitivity, Immune Response, Localization, Lymphocyte Proliferation, Parasitism, Pathogenesis, Phagocytosis, Programmed Cell Death, Secretion, T Cell Activation, Transport, Tropism, Virulence
Quite a number of genes have been found to play important roles in Leishmania Infantum Disease, such as CAT, CD4, CD8A, CPB1, CRAT, GLYAT, GPI, HAGH, HSPA4, IFNG, IL10, IL2, IL4, IL5, MDH2, MLC1, MPI, SLC6A3, TNF. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.